Back

EMPEROR-REDUCED Trial: main results.

29 August 2020 (18:31 - 18:50)
Organised by:
Congress Presentation Part of: New evidence on sodium-glucose transport protein 2 inhibitors therapy in heart failure patients Treatment Open Access ESC Congress 2020

About the speaker

Photo
Professor Milton Packer

Baylor University Medical Center, Dallas (United States of America)

4 More presentations in this session

Presentation thumbnail
Introduction.
Professor J. Butler (Dallas, US)
Video
Presentation thumbnail
SGLT2 inhibitors in HFrEF, a meta-analytical approach.
Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Video
Presentation thumbnail
Panel discussion
Professor G. Filippatos (Athens, GR) Professor F. Zannad (Vandoeuvre-Les-Nancy, FR) Professor J. Butler (Dallas, US) Professor S. Anker (Berlin, DE) Professor M. Packer (Dallas, US)
Video
Presentation thumbnail
Conclusion.
Professor M. Packer (Dallas, US)
Video

Access the full session

Session thumbnail
New evidence on sodium-glucose transport protein 2 inhibitors therapy in heart failure patients
Video

The Event

Event poster

ESC Congress 2020

29 August 2020 18:31 CET
You may be interested in
thumbnail
Congress Presentation
EMPEROR - Empagliflozin in Patients with Chronic Heart Failure
25 August 2023
thumbnail
Congress Presentation
Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial). a phase III study
27 August 2021
thumbnail
Congress Presentation
Benefits of empagliflozin in Hispanics and non-Hispanics with heart failure: a sub-analysis of the EMPEROR-trials
20 May 2023
thumbnail
Congress Presentation
Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in europe and israel: EMPRISE study results
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources